In this Phase II, double-blind study of primed and unprimed children aged 18–47 months, we demonstrated that the additional B strain in QIV did not compromise immunogenicity of existing strains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback